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ABSTRACT 
Objective 
Since the first study published in the Lancet in 1976, structural neuroimaging has been used 
in psychosis with the promise of imminent clinical utility. The actual impact of structural 
neuroimaging in psychosis is still unclear.  
Method 
We present here a critical review of studies involving structural magnetic resonance imaging 
techniques in psychotic patients published between the 1976-2015 in selected journals of 
relevance for the field. For each study we extracted summary descriptive variables. 
Additionally we qualitatively described the main structural findings of each articles in 
summary notes and we employed a biomarker rating system based on quality of evidence 
(scored 1-4) and effect size (scored 1-4).  
Results 
80 studies meeting the inclusion criteria were retrieved. The number of studies increased over 
time, reflecting an increased structural imaging research in psychosis. However, quality of 
evidence was generally impaired by small samples and unclear biomarker definitions. In 
particular, there was little attempt of replication of previous findings. The effect sizes ranged 
from small to modest. No diagnostic or prognostic biomarker for clinical use was identified.  
Conclusions 
Structural neuroimaging in psychosis research has not yet delivered on the clinical 
applications that were envisioned.  
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Summations 
Over the past four decades, structural neuroimaging has been used in psychosis with the 
promise of imminent clinical utility 
However, no diagnostic or prognostic biomarker for clinical use is available 
The lack of clinical utility of neuroimaging in psychosis is due to small samples, unclear 
biomarker definitions, and lack of replication. 
Considerations 
The current manuscript is not a systematic review of the literature and it may be affected by 
selection biases. 
 
INTRODUCTION 
At the dawn of in vivo brain imaging in psychiatry 
The desire to visualize the structure of the body has characterized medicine since its origins. 
Psychiatry and the brain are not different. The history of structural brain imaging began with 
radiographic techniques. However, since the brain is composed of soft tissue that is not radio-
opaque, it remained essentially invisible to plain x-ray investigations. The first attempt to 
visualize the brain traces back to 1918, when the neurosurgeon Walter Dandy(1), whose work 
on experimental hydrocephalus and cerebrospinal fluid circulation led to the development of 
pneumoencephalography(2). Most of cerebrospinal fluid was temporarily replaced trough a 
lumbar puncture with a contrast agent such as air, oxygen or helium, to improve brain 
contrast when imaging it with X rays. It was derived from ventriculography, an earlier 
method where the air was injected trough holes drilled in the skull of the patient. 
Pneumoencephalography become a common medical procedure mostly used to evaluate the 
size of the brain ventricles until the late 1970s. In 1927 Egas Moniz, neurologist and winner 
of the Nobel Prize in Physiology or Medicine (1949) for the discovery of leucotomy(3), 
introduced cerebral angiography, which allowed visualizing with great accuracy blood vessels 
in and around the brain(4). Drawbacks of these early methods was that that the signal to noise 
ratio was poor and since they were invasive techniques, the risk and discomfort for the 
patients were significantly high. 
 
Non-invasive mapping of the human brain structure 
The first non-invasive structural brain imaging method was computerized tomography (CT), 
developed in the late 1970s, when minicomputers and transverse axial scanning method 
became available. Transverse axial scanning was largely due to the work of Godfrey 
Hounsfield and Allan McLeod Cormack(5), who won the 1979 Nobel Prize for Physiology or 
Medicine for their work(6). With the CT available, better quality anatomical images of the 
brain became accessible to clinicians and researchers. About a decade later, in the early 
1980s, a second non-invasive structural brain imaging method, Magnetic Resonance Imaging 
(MRI), was introduced clinically. It was developed thanks to the work of several researchers 
who build its theoretical bases (for a detailed review see(7)), including Peter Mansfield and 
Paul Lauterbur. These researchers independently published in 1974 the technique that later 
became known as MRI, and were awarded the Nobel Prize for Physiology or Medicine in 
2003(8). With regard to patient safety, MRI is superior to CT scan because CT scan is using 
ionizing radiation, whilst MRI uses harmless radio waves. Consequently, over the following 
years it has become the gold standard method to visualize non-invasively human brain 
structure, with a veritable explosion of technical refinements and diagnostic MR applications.  
 
1976: The birth of structural brain imaging in psychosis 
Modern structural brain imaging in psychosis started in 1976, when Eve Johnstone and 
colleagues published the first brain computerized tomography study in psychotic patients 
(Figure 1)(9).  
 
*** Figure 1 *** 
 
The authors aimed at elucidating the relationship between brain structural change and 
deterioration of intellectual function in 17 chronic institutionalized patients affected with 
schizophrenia (aged 42-70) as compared to 8 age-matched healthy controls. Two brain 
images at comparable levels were selected for each patient: one showed the body of the 
lateral ventricles and the other showed the anterior and posterior horns of the lateral 
ventricles, together with the third ventricle. The area of the ventricles was then measured with 
a “planimeter” (9). The authors found that patients with schizophrenia performed significantly 
poorer than the control group on cognitive functioning. They also found a significant 
correlation between ventricular size and cognitive functioning, mostly relating to memory 
domains, within a subset of 13 patients. After excluding the patients who were leucotomized 
–a procedure that may cause an increase in ventricular size-, a significant ventricular 
enlargement was still observed, as compared to controls. The authors concluded that among 
patients with schizophrenia, “there is a group in which the disease is associated with 
increased ventricular size and impaired cognitive capacity” (9). It was therefore questioned 
whether “increased ventricular size is a consequence of the pathological process or whether 
increased ventricular size may in some way predispose to a severe and cognitively 
incapacitating form of the disease” (9). Further investigations “at different stages of the 
disease” (9) were recommended accordingly, to address these hypotheses.  
 
Forty years of structural brain imaging in psychosis: the promises 
Since the 1976 seminal study there has been an explosion of MRI or CT studies in psychiatry.  
Most of them were conducted in patients affected with psychosis(10). Structural 
neuroimaging has been embraced by investigators from different disciplines as a “window to 
the mind” to ultimately examine brain structure associated with psychotic disorders. A 
qualitative PubMed search uncovered an exponential increase of publications since 1976 
(n=5638, Figure 2), with about 200 structural imaging studies published per year over the 
recent three years. Structural neuroimaging has therefore promised much both to psychosis 
research and to clinical psychiatry.  
 
*** Figure 2 *** 
 
The ultimate promise for MRI was to deliver reliable biomarkers to impact the clinical 
practice for psychotic patients, defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention”(11). Biomarkers promised by MRI in 
psychosis were diagnostic (e.g. characterizing patients vs controls(12) or affective psychoses 
vs schizophrenic psychoses(13)), prognostic (e.g categorizing clinical high risk patients by 
degree of probability of psychosis onset(14)), predictive (categorizing psychotic patients by 
their likelihood for response to antipsychotics(15) or cognitive enhancement therapy(16)), 
pharmacodynamic (showing that a gray matter alterations have occurred in psychotic patients 
after having received antipsychotics(17)), surrogate (intended to substitute for another clinical 
efficacy end point). The ultimate promise of MRI was to “bring neuroscience into clinical 
practice”(18), by playing “a major role for a biological foundation of psychiatric 
diagnoses”(19) or by informing “tailored intervention strategies” (20) and leading “to more 
rational and efficacious treatment strategies than are available today”(21). 
 
 The principal aim of the current review is to critically assess to what extent these 
promises have been maintained or not. We present here a critical review of studies 
involving structural magnetic resonance imaging techniques in psychotic patients 
published between the 1976-2015 in critically selected journals of relevance for the 
field.  
 The second aim is to assess the included studies with a biomarker rating system based 
on quality of evidence and effect size.  
 The third aim is to integrate the results and to suggest possible directions for future 
research.   
 
METHODS 
Type of review 
We performed a critical review of the literature to address the impact of structural imaging in 
psychosis.  
 
Literature search 
Given MRI has become the gold standard method to investigate in vivo structural alterations 
we have selectively restricted our search to MRI studies conducted in patients affected with 
psychosis. Furthermore, we have restricted our search to a critical selection of journals of 
significant relevance in the field of psychiatric neuroimaging: The Lancet, Archives of 
General Psychiatry/JAMA Psychiatry, Molecular Psychiatry, American Journal of Psychiatry, 
Brain. Literature search was conducted in Web of ScienceSM, MEDLINE® and Scopus®. The 
search was extended until September 23rd 2015, and included abstracts in English language 
only. The electronic research adopted combinations of the above journal names with the 
following keywords: “psychosis”, “mri”, “schizophrenia”. Journal selection and literature 
search were not intended to fulfil the requirements for a systematic and comprehensive 
review of all MRI studies in psychosis. 
 
Inclusion and exclusion criteria 
We included original English studies using MRI methods in patients with psychosis published 
in any of the journals listed above here. We used a broad spectrum definition of psychosis 
also including patients with a genetic or clinical risk for the illness. We excluded abstracts or 
studies employing other structural, functional, neurochemical imaging methods such as 
Diffusion Tensor Imaging (DTI), functional Magnetic Resonance Imaging (fMRI), Positron 
Emission Tomography (PET), and Magnetic Resonance Spectroscopy (MRS). 
  
Data extraction and analysis 
For each study we extracted study ID, MRI method, illness stage, sample size of psychotic 
patients, sample size of controls. Additionally we qualitatively described the main structural 
findings of each articles in summary notes.  
 
Biomarker assessment 
To assess the clinical applicability of MRI findings in psychosis we adapted a biomarker 
rating system proposed by Lassere(22) and previously used in early psychosis 
populations(23). The scale is based on quality of evidence (scored 1-4) and effect size (scored 
1-4). To assess quality of evidence we extracted a number of moderator factors that were 
considered in each study. We then qualitatively rated the level of evidence for a potential 
biomarker(23):  
 0 for uncontrolled studies;  
 1 in a study controlled for relevant extraneous variables, that is, matched, restricted or 
adjusted for at least four of the followings: illness stage, antipsychotic exposure, age, 
gender, IQ, socioeconomic status, ethnicity, type of psychotic diagnosis;  
 2 in a study as above (grade 1) but with an explicit a priori intent to discover a 
precisely defined biomarker for psychosis, that is, within a given measure or modality, 
cut-off and direction of effect of biomarker and response;  
 3 in studies as above (grade 2), but designed with adequate power informed by 
previous positive studies of the same biomarker, that is, replication in an independent 
cohort;  
 4 in at least two studies as above (grade 3). 
Effect size was estimated for the main finding of each study with Cohen’s d and then rated as 
follows(23): 
  0 with estimates from studies with quality of evidence ≤ 1 
 1 with marginal effect (Cohen’s d <0.2) 
 2 with small effect size (Cohen’s d ≤from 0.2 to 0.5)  
 3 with medium effect size (Cohen’s d from 0.5-0.8) 
 4 with a large effect size (Cohen’s d > 0.8) 
The sum of the two scores was then used to assess the clinical applicability of a biomarker, 
using the cutoff of >6 previously indicated(23). Results were summarized with descriptive 
statistics and qualitatively described.  
 
RESULTS  
Database 
A total of 80 studies published over the past four decades were included in our database, for a 
total of over than 11,000 patients with a psychotic spectrum disorder.  
 
Descriptive summary of findings 
After the first qualitative study(24) indicating that “MRI showed superiority to CT in 
visualisation of” brain structures, all of subsequent studies employed MRI. Most of them 
investigated grey matter volumes in psychotic patients as compared to healthy controls. 
Consequently, grey matter volume studies were the most frequent ones and were 
characterised by significant advancements in analytical methods and data processing 
techniques over time. For example, the first grey matter volume study(25) covered in our 
database focused on medial temporal lobe and ventricles abnormalities in a small sample of 
66 first episode patients, while a recent multisite meta-analysis has investigated about 2028 
patients and 2540 controls on different brain regions, uncovering smaller hippocampus, 
amygdala, thalamus, accumbens, and intracranial volumes and larger pallidum and lateral 
ventricle volumes in patients(26). As soon as voxel based morphometry methods were 
introduced in cognitive neurosciences, in 2000(27) (for an example of one of the first studies 
see(28)), such analytical approaches were immediately adopted in psychosis research(29), and 
were then followed by other studies(16, 30-33). Following emerging interest in more derived 
measures of anatomy such as cortical complexity, gyrification, symmetry and thickness(34), a 
few studies have addressed these alterations in psychotic patients(15, 35-42). Multimodal 
studies involved the use of MRI, eye tracking and markers of dopamine activity(25), MRI and 
PET(43), MRI and EEG measures(44), MRI and fMRI(40, 41), MRI and genetics(32, 38, 45, 
46). Most studies focused on first-episode samples, with several MRI studies investigating the 
psychotic spectrum by including samples at genetic risk(28, 33, 37, 47-55) and a few studies 
that have investigated subjects at clinical risk for psychosis(14, 31, 56-58). One meta-analysis 
has investigated the human connectome in healthy brains as well as in psychotic disorders(59). 
Two recent studies adopted machine learning methods in patients with early psychosis or at 
clinical high risk for psychosis(57, 58). The list of all included studies and the main structural 
findings are detailed in Table I. 
 
*** Table I  *** 
 
Clinical applicability of MRI-based biomarkers for psychosis 
The ratings for the level of evidence of potential biomarkers and for the effect size of each 
included studies are detailed in Table I. None of the 80 studies but one(58) met the a-priori 
cutoff criteria for a potential clinical applicability in psychosis described above. This study 
used study used structural MRI-based multivariate pattern classification to identify and cross-
validate a differential diagnostic signature separating patients with first-episode and recurrent 
stages of schizophrenia (n = 158) from patients with major depression (n = 104) and to 
quantify the impact of major clinical variables, including disease stage, age of disease onset 
and accelerated brain ageing on the classification performance. The diagnostic MRI signature 
was then externally validated in an independent patient cohort to test its generalizability to 
individuals with bipolar disorder (n = 35), first-episode psychosis (n = 23) and clinically 
defined at-risk mental states for psychosis (n = 89). The authors found that their 
neuroanatomical diagnosis was correct in 80% and 72% of patients with major depression and 
schizophrenia, respectively, and involved a pattern of prefronto-temporo-limbic volume 
reductions and premotor, somatosensory and subcortical increments in schizophrenia versus 
major depression. Furthermore, they found that diagnostic performance was not influenced by 
the presence of depressive symptoms in schizophrenia or psychotic symptoms in major 
depression, while earlier disease onset, accelerated brain ageing and disease stage 
significantly moderated neuroanatomical diagnosis. In their validation study, the trained 
biomarker assigned 74% of the bipolar patients to the major depression group, while 83% of 
the first-episode psychosis patients and 77% of the individuals with an clinical high risk state, 
respectively, were labeled with schizophrenia. Replication studies were scarce, although this 
may have been influenced by our critical literature search that was restricted to high impact 
factor journals(60). 
 
DISCUSSION  
Forty years of structural brain imaging in psychosis: the truth 
Despite the enduring efforts and the impressive number of MRI studies published in 
schizophrenia patients (more than 5,000, see Figure 2), there are no clinical biomarkers for 
structural MRI in psychosis. Recent systematic reviews and meta-analyses of the available 
evidence have identified specific cortical and subcortical alterations in psychotic patients as 
compared to healthy controls (for a detailed review on the main findings see(61, 62)). Yet, 
after four decades of research, the conclusion of the first 1988 study included in our database 
“none of the findings from CT or MRI explained clinical observation or led to a change in 
treatment”(24) are still valid. As recently confirmed by positional statements by leading 
authors, imaging research has yielded no clinical advancement for psychotic patients (see 
Table II).  
 
*** Table II *** 
 
This is further confirmed by our empirical analysis, which uncovered only one study 
satisfying the basic requirement for some potential clinical applicability of biomarkers in 
psychosis(58). This study suggested that neuroanatomical classification could provide 
generalizable diagnostic tools distinguishing schizophrenia from mood disorders early in the 
course of psychosis. However, it is important to note that the assessment of the theoretical 
clinical applicability per se does not assure real-world clinical utility(23). Indeed, proper 
randomised clinical trials (of this biomarker vs standard care) should be carried out so that 
additional factors such as cost of administration, potential risks and side effects, 
inconvenience and delays associated with testing can be balanced and a decision on its real-
world clinical utility can then be made(23). Because of this, the clinical utility of the 
biomarker described by this unique study is still in need of additional converging support. 
This is particularly relevant given that the brain areas implicated by this study are only 
partially consistent with the largest MRI analysis in schizophrenic patients(26). Similarly, 
structural imaging is not clinically recommended for the differential diagnosis of incidental 
organic psychoses due to underlying brain abnormalities. A recent review of 1379 MRI scans 
found that none of the neuropathological findings observed in the patients represented a 
possible substrate for organic psychosis, concluding that MRI brain scans should not be an 
essential part of routine screening for psychotic patients(63). On the basis of these findings, 
the current NICE guidelines do not recommend the use of structural neuroimaging for 
routinely examine all patients who have suffered from a first episode of psychosis(64). We 
will address practical and conceptual issues underlying this clinical failure of structural 
imaging in psychosis in the following sections. 
 
The role of confounders and the lack of valid biomarker in psychosis 
It is possible that several external factors may have played a confounding role impacting the 
lack of reliable MRI biomarker in psychosis. Early MRI studies identified in our literature 
search have soon highlighted the confounding role played by illness chronicity and 
antipsychotic exposure(65, 66). Since then, most of MRI studies have controlled their results 
for these factors. The development of the clinical high-risk paradigm, as well as the study of 
identified risk factors such as genetic polymorphisms or environmental exposures in health 
individuals has further allowed researchers to investigate putative biomarkers of an risk of 
psychosis in antipsychotic-naïve participants with no impact of illness chronicity or 
medication(62). Structural imaging studies in subjects at clinical high risk for psychosis have 
been summarized by voxel based meta-analyses indicating that psychosis onset is 
characterized by gray matter decreases in temporal, anterior cingulate, cerebellar, and insular 
regions(62). Furthermore, gray matter alterations in the temporal regions directly related to 
severity of psychotic symptoms(62). However, despite these promising findings, no reliable 
biomarker of psychosis risk has been validated to clinically predict the onset of the disorder. 
This may be in part due to the fact that the group of subjects at clinical high risk for psychosis 
is not heterogeneous as it includes different clinical subgroups(67, 68).  
Additional modulators of brain structure in psychosis may include age(69), gender(70), type 
of psychotic disorder (e.g. schizophrenia spectrum disorders vs affective psychotic 
disorders(71)), smoking(72), ethnicity(73), substance abuse(74), all of which have been 
shown to impact on the MRI signal. However, over the recent years authors have become 
more aware of these caveats, controlling their MRI studies for these factors. It is thus unlikely 
that the confounding factors alone could be responsible for the global lack of clinical reliable 
biomarkers in psychosis research.  
 
Small samples and reporting biases in structural imaging of psychosis 
Conversely, recent empirical evaluations of the neuroimaging literature suggest that study 
publication bias, selective outcome reporting bias, and selective analysis reporting bias are 
prevalent across diverse domains of cognitive science(75). There is specific evidence that 
these biases may affect both region of interest(76) and voxel based morphometry (VBM) 
(77)) structural imaging studies of psychotic patients.  
 
Reporting biases may specifically affect small structural imaging studies and even meta-
analyses with few studies, inflating the number of significant findings(77). Consequently, 
there has been a trend towards larger structural imaging studies of psychotic patients over 
time. This trend is observed in our database with an average sample size of 53 psychotic 
patients for the MRI studies conducted before 2000, 57 patients for the studies conducted 
between 2000-2005, 97 patients for studies published between 2005-2010 and 179 patients 
for studies conducted over the 2015-2010, with two meta-analytical outliers conducted in 
about 2000 psychotic patients(41, 59). An independent review confirmed our findings by 
concluding that there is limited evidence supporting grey or white matter changes in 
schizophrenia, which has previously been obscured by a large volume of conflicting, lower 
quality evidence(78). However, reporting biases are by no means specific or confined to 
psychiatric conditions(77) and are thus unlikely to account for the overall lack of reliable 
biomarkers in psychosis research. Available statistical tests and approaches to prevent bias 
have been made available (75)) which could improve the quality of structural imaging reports 
in the future. 
 
Machine learning methods: myth or promising avenue? 
Since no simple regional or global neuroanatomical measure has been unequivocally 
associated with psychosis, researchers started investigating more complex patterns of brain 
alterations with advanced analytical methods. Indeed, the one study identified by our 
literature search meeting advanced criteria for biomarker detection was based on machine 
learning methods, and delivered a neuroanatomical-based biomarker to differentiate 
schizophrenia from mood disorders early in the course of psychosis(58). Machine learning 
methods are one of today’s most rapidly growing technical fields, lying at the intersection of 
computer science and statistics, and at the core of artificial intelligence and data science (for a 
review of machine learning methods in modern sciences see(79)). Machine learning methods 
may ultimately address the complexity of psychotic disorders capitalizing on the abilities of 
machines to tease out subtle statistical regularities from massive data sets(79). Because of this, 
machine learning methods are fast becoming the mainstream analytical avenue for modern 
neuroimaging studies of psychiatric disorders (see Figure 3 for a summary of its method).  
 
*** Figure 3 *** 
 
Authors hope that in the near future these methods applied in psychosis “might help clinicians 
in reliable and early detection of affected patients, potentially becoming a crucial tool for the 
real world of psychiatric practice”(80). However, “nowadays we are far away from using 
automatic image-based classification techniques to make a diagnosis” (80), and the 
limitations of these methods are often underreported. For example, the majority of studies 
have tried to discriminate patients with a particular DSM/ICD diagnosis (e.g. schizophrenia) 
from healthy controls, or to disambiguate between patients from different DSM/ICD-defined 
disease states. Therefore, machine-learning approaches which use diagnostic labels from 
DSM/ICD for training a classifier applied to neuroimaging data are using a sophisticated 
procedure(81) to replicate a diagnostic classification that may in itself be biologically 
problematic. An additional, more generic risk of machine learning is that these approaches 
tend to deliver what are effectively ‘black-box’ classifiers, which are statistically powerful 
but may provide very limited insights into disease mechanisms(81). This is a fundamental 
limitation, since without mechanistic interpretability a diagnostic procedure will be ill placed 
to promote a change in disease concepts or guide the development of future therapies(81). 
 
Structural neuroimaging in other neuropsychiatric disorders 
Contrary to clinical psychiatry, structural imaging is already in use as clinical diagnostic 
criterion for other complex neuropsychiatric disorders, for example for the most prevalent 
non-Alzheimer Dementias (AD): vascular dementia, frontotemporal degeneration, dementia 
with Lewy bodies, and Creutzfeldt–Jakob disease(82). With respect to AD, the recent 
guidelines of the Alzheimer's Association and the National Institute on Aging (NIA) have 
detailed the differential diagnostic impact of structural neuroimaging for the three phases of 
the disorder: dementia due to Alzheimer's (probable AD dementia, possible AD dementia, 
probable/possible AD dementia with evidence of the AD pathophysiological process)(83), 
mild cognitive impairment (MCI) due to Alzheimer's(84) and preclinical (presymptomatic) 
Alzheimer's(85). For established AD dementia (possible or probable) “the use of AD 
biomarker tests for routine diagnostic purposes at the present time” is not advocated neither 
required for the diagnosis(83). However, the field is more advanced as compared to psychosis 
since in persons who meet the core clinical criteria for probable AD dementia, biomarker 
evidence “may increase the certainty that the basis of the clinical dementia syndrome is the 
AD pathophysiological process”(83). These biomarkers are well defined and include 
structural measures such as atrophy on structural MRI in media, basal, and lateral temporal 
lobe and medial parietal cortex(83). Similarly to the prodromal phase of psychosis, the high 
risk MCI diagnosis can be formulated “without access to advanced imaging techniques” (84). 
However, a separate set of research criteria is already available, which include a number of 
biomarkers(86) reflecting signs of neuronal injury(84). Of relevance, the guidelines outline a 
probabilistic framework for the way in which biomarkers may be used to provide increasing 
levels of certainty that AD pathology is the cause of an individual’s clinical symptoms 
(cognitive decline) (84). This is a significant advancement as compared to psychosis research 
where no clear guidelines are put forward. For example, cortical thinning/gray matter loss in a 
specific anatomic distribution (i.e., lateral and medial parietal, posterior cingulate, and lateral 
temporal cortices) and/or hippocampal atrophy on volumetric MRI are clearly indicated as 
leading biomarkers for the diagnosis of preclinical AD(85).  
 
The lack of gold standard and the exceptionalism of the human being 
A core difference between psychosis and other complex neuropsychiatric disorders such as 
AD is that, unlike AD, there is no objective neuropathological gold standard for psychotic 
diagnoses. Unlike our definitions of other medical conditions such as ischemic heart disease, 
lymphoma, or AIDS, the psychotic “diagnoses are based on a consensus about clusters of 
clinical symptoms, not any objective laboratory measure”(87). Indeed a recent meta-analysis 
of structural studies across several psychiatric disorders such as schizophrenia, bipolar 
disorder, depression, addiction, obsessive-compulsive disorder, and anxiety found converging 
gray matter loss in the same brain areas with a few diagnosis-specific effects(88). Because of 
these nosographic limitations, the NIMH has launched the Research Domain Criteria (RDoC) 
project to transform psychiatric diagnoses by the mean of genetics, imaging, cognitive science, 
and other levels of information to lay the foundation for a new classification system based on 
neurobiology. Rather than seek MRI biomarkers that can ‘diagnose’ clinically defined 
disorders, RDoC will help future MRI studies focusing on identifying biologically 
homogenous subtypes that potentially cut across phenotypic diagnosis—thereby sidestepping 
the issue of a gold standard(89). However, this approach may be “over-promising about the 
future blithely ignored the sobering lessons of the past(90)” 40 years of imaging research. The 
claim that this approach is substantially different from those endorsed in the past decades, that 
were unable to produce significant biomarkers, is not supported by preliminary findings(91). 
On the other hand, it stands to reason that mapping data such as structural neuroimaging onto 
criteria or scales closer to the underlying pathologie(s) of the clinical states of interest is more 
informative, especially if multivariate techniques are employed whose output may be 
intrinsically harder to interpret mechanistically.  
 The future of structural neuroimaging in psychosis 
Although the spatial resolution of modern MRI protocols is very high, 1 mm3 of cortical gray 
matter can contain up to 60,000 neurons, up to four times as many glial cells per neuron, as 
well as neuronal processes, blood vessels, intracortical myelin and dendritic spines. Therefore, 
alterations found at a cellular/synaptic/microstructural level, may not be visualized with 
current MRI techniques(92). However, it may be time to consider the alternative possibility 
that brain structure, while certainly altered in the majority of patients with psychosis, may 
never be – in isolation - a useful biomarker for psychosis just as high blood pressure, while 
certainly altered in the majority of patients with type II diabetes, is not a useful biomarker for 
this condition. In other words, if structural brain alterations are too far downstream or only 
distantly related to causal pathology of psychotic illness, they may not index informative 
biology related to the clinical critical parameters of differential diagnosis and prediction of 
course and therapeutic stratification. Some evidence for this assumption comes from imaging 
genetics, which studies the arguably biologically best defined risk factors for the highly 
heritable disease of schizophrenia in the absence of many confounds discussed above. Here, 
the experience is that structural neuroimaging measures underperform functional 
neuroimaging measures when the effects of common genetic variants are mapped(93, 94). 
Recent work by the psychiatric GWAS consortium and the ENIGMA consortium further 
supports this by indicating that polygenetic risk scores for schizophrenia fail to explain 
meaningful variance in even very large neuroimaging datasets. A recent study integrating 
common variant studies of schizophrenia (33,636 cases, 43,008 controls) and volumes of 
several (mainly subcortical) brain structures (11,840 subjects) found no evidence of genetic 
overlap between schizophrenia risk and brain volume measures either at the level of common 
variant genetic architecture or for single genetic markers(95). There are several potential 
neurobiological reasons that might underlie such an absence, notably the fact that 
schizophrenia is a neurodevelopmental process where several neural longitudinal changes 
may map in opposite fashion onto regional volumes (for example, cortical pruning as a 
mechanism of maturation in adolescence and pathology-induced neuronal loss both may lead 
to cortical thinning; antipsychotic treatment and neural plasticity may both lead to same-
direction volume changes in the striatum). By the same token, the usefulness of structural 
imaging biomarkers may potentially be much enhanced if information from other sources, 
some of which – functional neuroimaging, for example of the resting state – can be measured 
in the same sitting, is included. This might extend to genetic and clinical information, for 
example. Machine learning, with all the problems inherent in its interpretation discussed 
above, lends itself to that approach, as well. 
 
CONCLUSIONS  
The current critical review suggests that structural neuroimaging in psychosis research has not 
(yet) delivered on the clinical applications that were envisioned. Several reasons for this as 
yet disappointing outcome have been discussed. Better nosological criteria, biomarker studies 
at a higher methodological standard, biomarkers including complementary information (such 
as functional and clinical data) may yet resolve that impasse. Until then, after four decades of 
promises, in their everyday practice, psychiatrists continue talk to the patients, use 
observation, description and classification, test explanatory hypotheses, and formulate clinical 
decisions in the absence of such structural biomarkers.  
FIGURES 
Figure 1. First modern computerized tomography of the brain in psychotic patients (1976). 
Patients affected with psychosis showed enlarged ventricular size as compared to healthy 
controls. White dots indicate leucotomised psychotic patients. From(9) 
 
Figure 2. Number of PubMed studies employing MRI or CT in schizophrenia over the past 
four decades, up to 2015 (keywords “mri”, “schizophrenia”, search date 28rd May 2016, 
number of records=5638). 
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Table 1 
Study ID 
Method  
Psychosis 
group 
Patients 
(n) 
Controls 
(n) 
Main structural finding 
Biomarker 
Quality of 
evidence 
Effect 
size 
Chung 2015(42) Cortical Thickness CHR (1) 274 135 Among CHR-T, higher levels of baseline unusual thought content 
related to steeper rate of GM loss in the bilateral prefrontal cortex 
and with third ventricle expansion.  
2 2 
Koutsouleris 
2015(58) 
Machine Learning 
Validaton 
FEP,  ChP 
FEP, CHR 
158      
112(3) 
104(2) 
35(4) 
Neuroanatomical diagnosis based on a biomarker involving a 
pattern of prefronto-temporo-limbic volume reductions and premotor, 
somatosensory and subcortical increments correctly identified 83% 
of patients with first episode psychosis and 77% of CHR subjects. 
3 4 
Lesh 2015(41) Cortical Thickness + 
fMRI 
FEP  45(5) 37 Short-term treatment with antipsychotics associated with increased 
prefrontal functional activity, better cognitive control but prefrontal 
cortical thinning. 
2 3 
van Erp 2015(26) Meta-analysis of grey 
matter volume 
ChP 2028 2540 Compared with healthy controls, patients with schizophrenia had 
smaller hippocampus, amygdala, thalamus, accumbens, and 
intracranial volumes and larger pallidum and lateral ventricle 
volumes.  
3 2 
Crossley 
2014(59) 
Meta-analysis of 
connectome 
ChP 1925 2133 Schizophrenia had significantly hub-concentrated lesion 
distributions, with lesions were concentrated in both frontal and 
temporal cortical hubs. 
0 0 
Hoptman 
2014(40) 
Cortical Thickness + 
fMRI 
ChP 33 31 Impulsivity correlated with reduced cortical thickness in the right 
frontal pole, the medial and lateral orbitofrontal gyrus and inferior 
frontal gyri, and the rostral anterior cingulate cortex. 
1 0 
Mathew 2014(96) Hippocalmpal volume ChP 508(6) 337 Hippocampal volume reductions in schizophrenia, schizoaffective 
and psychotic bipolar patients, alterations in entorhinal cortex and 
parahippocampal regions in schizophrenia and schizoaffective only.   
1 0 
van Lutterveld 
2014(39) 
Cortical thickness ChP 100(7) 50 Individuals with non-clinical psychotic symptoms show a similar but 
less pronounced pattern of cortical thinning as patients with a 
psychotic disorder. 
2 na 
Ivleva 2013(33) VBM ChP, GHR 720(8) 200 Extensive neocortical GM reductions in psychosis probands and 
relatives with psychosis spectrum disorders. Partially divergent GM 
phenotypes for probands with schizophrenia of schizoaffective 
disorder relative to those with psychotic bipolar disorder. 
2 1 
Palaniyappan 
2013(15) 
Cortical gyrification FEP(9) 80 46 Reduction in gyrification across multiple brain regions. Non-
responders to antipsychotics showed prominent hypogyria at 
bilateral insular, left frontal and right temporal regions when 
compared with responders.  
1 0 
Arango 2012(97) Gray matter volume COP 61 70 Patients with schizophrenia or other psychoses showed greater loss 
of GM matter volume and increase of CSF in the frontal lobe relative 
to controls. 
2 2 
Tan 2012(32) VBM+genetic ChP 118(10) 20(10) Patients with the AKT1-A-allele who were also on mood stabilizer 
had larger GM volume in the medial temporal lobe and prefrontal 
cortex than patients not receiving mood stabilizers. 
1 0 
Wassink 
2012(45) 
Gray matter 
volume+genetic 
ChP 335 198 The results did not substantiate previously reported effects of 
rs1344706 on cerebral cortical GM volume. 
1 0 
Bakken 2011(38) Cortical Thickness + 
genetic 
ChP 94 181 Two closely linked variants within the Prader-Willi and Angelman 
syndrome on chromosome 15q12 showed a genome-wide 
significant association with average cortical thickness among 
patients with schizophrenia. 
1 0 
Ho 2011(98) Gray matter volume ChP 211 - Greater intensity of antipsychotic treatment was associated with 
indicators of generalized and specific brain tissue reduction. Illness 
severity had relatively modest correlations with tissue volume 
reduction. 
0 0 
Mechelli 
2011(31) 
VBM CHR(11) 182 167 The UHR group had less prefrontal GM volume than controls in the 
frontal regions bilaterally. GM reductions in the left parahippocampal 
were associated with psychosis onset. 
1 0 
Prasad 2011(99) VBM FEP 18(12) 24(12) HSV1 exposure associated with longitudinal GM loss in the posterior 
cingulate gyrus and decline in executive functions in schizophrenia. 
1 0 
Eack 2010(16) VBM ChP 30(13) 23(13) Within patients, cognitive enhancement therapy associated with GM 
preservation in the left hyppocampus, parhyppocampal gyrus, 
fusiform gyrus and significantly GM increase in left amygdala. 
2 3 
Gilmore 2010(55) Gray matter volume GHR 26(14) 26(14) Offspring of mothers with schizophrenia did not differ in prenatal 
lateral ventricle width. Male neonates at genetic risk for 
schizophrenia had several larger than normal brain volumes. 
2 3 
Goldman 
2009(37) 
Cortical Thickness ChP, GHR 307 196 Widespread cortical thickness reductions in schizophrenia and 
widespread evidence for heritability for cortical thickness reduction 
throughout the brain. 
2 na 
Koutsouleris 
2009(57) 
Machine learning 
Validation 
CHR 45(15)         
33(16) 
25          
17 
Whole-brain neuroanatomical abnormalities classified by machine 
learning algorithms may serve as valuable biomarker to 
distinguishing between CHR and control and from CHR developing 
psychosis or not (accuracy 86%-96%).  
3 2 
Takahashi 
2009(100) 
Gray matter volume CHR, FEP 58(17) 22 Progressive GM loss in volumes of the superior temporal subregions 
are associated with the onset of psychosis. 
2 3 
Brans 2008(101) Gray matter volume ChP, GHR 38(18) 54 Significant additive genetic influences on the correlations between 
schizophrenia liability and progressive whole brain, frontal lobe, and 
temporal lobe volume change. 
1 0 
Keller 2008(102) Gray matter volume ChP 23 22 Depressed patients with psychosis had a smaller amygdala volume 
relative to depressed patient without psychosis and healthy 
comparisons. 
1 0 
Koo 2008(103) Gray matter volume FEP 80 40 In schizophrenia, significantly smaller left subgenual, left and right 
affective subregion, right cognitive, and right posterior cingulate 
gyrus GM compared with controls and progressive GM decreases in 
the cingulate subregions at follow-up. 
2 3 
Addington 
2007(46) 
Gray matter 
volume+genetic 
COP 59 165 In COP patients, neuregulin risk allele 0 at 420M9-1395 carriers had 
greater total GM and white matter volume in childhood and a 
steeper rate of subsequent decline in volume into adolescence. 
1 0 
Kuroki 2006(104) Gray matter volume FEP 40 23 Smaller GM volumes in left and right middle temporal gyri and left 
superior temporal gyrus in schizophrenia but not in affective 
psychosis. Smaller bilateral posterior inferior temporal gyrus GM 
volume in both schizophrenia and affective psychosis. 
1 0 
McDonald 
2006(54) 
Gray matter volume ChP, GHR 189(19) 54 Schizophrenia and psychotic bipolar disorder are characterized by 
morphometric distinctions in ventricular and hippocampal regions. 
Lateral ventricular enlargment as morphometric endophenotype for 
schizophrenia. 
2 4 
Velakoulis 
2006(56) 
Gray matter volume ChP, FEP, 
CHR 
386(20) 87 Chronic schizophrenia associated with bilateral hippocampal volume 
reduction. FEP schizophrenia associated with left hippocampal 
volume reduction. CHR subjects had normal baseline hippocampal 
and amygdala volume whether or not they subsequently developed 
a psychotic illness. 
2 3 
Vidal 2006(36) Cortical pattern COP, FEP 21(21) 12 Selective, frontal GM loss occurred bilaterally in a dorsal-to-ventral 
pattern across the medial hemispheric surfaces in schizophrenia. 
2 na 
Coryell 
2005(105) 
Gray matter volume ChP 20 10 Posterior subgenual prefrontal cortex is smallest for psychotic major 
depressive disorders patients as compared to controls or patients 
with schizophrenia. 
2 3 
Ho 2005(106) Gray matter volume FEP 57(22) 48(22) No significant associations between hippocampal volumes and 
duration of untreated initial psychosis. 
1 0 
Lieberman 
2005(107) 
Gray matter volume FEP 161 58 Haloperidol-treated patients exhibited significant decrease in GM 
volume, whereas olanzapine-treated patients did not.  
2 2 
Nierenberg 
2005(108) 
Gray matter volume FEP 14 14 Patients with new-onset schizophrenia showed smaller left angular 
gyrus volume than normal subjects 
0 0 
Suzuki 2005(109) Gray matter volume ChP 78(23) 59 Volume reductions in the amygdala and hippocampus are the 
common morphological substrates for the schizophrenia spectrum. 
2 3 
Wiegand 
2005(35) 
Cortical complexity FEP 34 17 Schizophrenia patients showed less left-greater-than-right 
asymmetry in cortical complexity thant the comparison subjects. 
1 0 
Dazzan 2004(30) VBM FEP  34(24) 39(24) In FEP patients a higher rates of soft neurological signs are 
associated with a reduction of GM volume of subcortical structures.  
1 0 
Robinson 
2004(110) 
Gray matter volume FEP 107(6) - In FEP patients, more cerebral asymmetry was associated with full 
recovery and adequate social/vocational functioning 
0 0 
Ettinger 
2004(111) 
Gray matter 
volume+antisaccades 
FEP 20 18 FEP significantly differed from controls in terms of antisaccade error 
rate and amplitude gain but not brain region volumes. 
1 0 
Gogtay 
2004(112) 
Gray matter volume COP 42(25) 38 COP patients had significantly greater total, frontal and temporal and 
parietal GM loss as compared to controls and psychosis not 
otherwise specified. 
2 3 
McDonald 
2004(53) 
Gray matter volume ChP, GHR 148(26) - Genetic risk for schizophrenia was specifically associated with 
distributed GM volume deficits in the bilateral fronto-striato-thalamic 
and left lateral temporal regions. 
0 0 
Prasad 
2004(113) 
Gray matter volume FEP 44 43 Patients with schizophrenia and non schizophrenic psychoses had 
smaller left entorhinal cortex volume than healthy subjects.  
2 2 
van Erp 2004(52) Gray matter volume ChP, GHR 110(27) 109 Probands had smaller hippocampal volumes than did their full 
siblings, who in turn had smaller hippocampal volumes than did the 
healthy comparison subjects.  
2 4 
Ho 2003(114) Gray matter volume FEP 102 - Within FEP patients, untreated initial psychosis has no direct impact 
on GM volume and toxic neural effects. 
0 0 
Kasai 2003a(115) Gray matter volume FEP 28 14 Progressive volume reduction of the left superior temporal gyrus GM 
in patients with schizophrenia as compared to affective psychosis or 
controls. 
1 0 
Kasai 2003b(13) Gray matter volume FEP 53 29 Partially different and partially similar structural abnormalities in 
olfactocentric paralimbic and temporolimbic regions are important 
factors in the differential and common manifestations of affective 
and schizophrenic psychoses. 
1 0 
Kasai 2003c(116) Gray matter volume FEP 28 22 FEP schizophrenia showed significant decreases in GM volume over 
time in the left Heschl gyrus and left planum temporale vs patients 
with FEP affective psychosis and controls. 
1 0 
Keshavan 
2003(117) 
Gray matter volume FEP 26 18 In schizophrenia, higher score for the cognitive/perceptual 
abnormalities factor correlated with smaller volumes of the left 
heteromodal association cortex. 
1 0 
Pantelis 2003(14) Gray matter volume CHR 23(28) 52(28) CHR patients who did develop psychosis had less GM in the right 
medial temporal, lateral temporal, and inferior frontal cortex, and the 
cingulate cortex bilaterally, compared with CHR who didn't develop 
psychosis.  
2 na 
Szeszko 
2003(118) 
Gray matter volume FEP 46 34 Patients had reduced anterior hippocampal volume relative to 
control subjects.  
2 2 
Cannon 2002(51) Gray matter volume Chronic, 
GHR 
115(29) 54 Fetal hypoxia predicted reduced GM trough the cortex in the 
patients and siblings. 
1 0 
Lee 2002(119) Gray matter volume FEP 42 24 Schizophrenia associated with smaller fusiform gyrus GM volume 
compared with controls and patients with affective psychosis. 
1 0 
McCarley 
2002(44) 
Gray matter 
volume+P300 
FEP 33 18 Schizophrenia showed smaller GM volumes of left posterior superior 
temporal gyrus related to control and affective psychosis. These 
alterations were correlated with P300 abnormalities.  
1 0 
Seidman 
2002(50) 
Gray matter volume ChP, GHR 63(29) 48 Relatives, compared to controls, had significantly smaller left 
hippocampi, reflecting core genetic liability to schizophrenia. 
2 2 
Sumich 
2002(120) 
Gray matter volume FEP 25 16 Patients had smaller bilateral hippocampal and planum temporale 
volumes than the comparison subjects.  
2 4 
van Herp 
2002(49) 
Gray matter volume ChP, GHR 130(30) 53 Patients had smaller hipocampal volumes than did their full siblings, 
who in turn had smaller hippocampal volumes than did the healthy 
comparison subjects. Smaller hippocampal volumes in fetal hypoxia 
patients. 
2 2 
Ettinger 
2001(121) 
Gray matter volume FEP 38 29 Thalamic volumes were smaller in patients.  1 0 
Hulshoff Pol 
2001(122) 
Gray matter density ChP 159 158 GM density is decreased in several distinct focal areas in ChP, with 
an age effect in left amygdala. 
1 0 
Matsumoto 
2001(123) 
Gray matter volume COP 40 40 GM volume of the right superior temporal gyrus was significantly 
lower in patients with early onset-schizophrenia than in the controls. 
1 0 
Shihabuddin 
2001(43) 
Gray matter 
volume+PET 
ChP 58(31) 47 Smaller size of putamen in schizophrenia as compared to controls. 
Glucose metabolism reduced in schizophrenia. 
2 2 
Vogeley 2001(48) Cortical gyrification ChP, GHR 12(32) 12(32) Gyrification index on the right side was significantly higher in siblings 
with schizophrenia or schizoaffective disorder than in unaffected 
siblings. 
0 0 
Fannon 
2000(124) 
Gray matter volume FEP 37 25 Patients had deficits in cortical GM, temporal lobe GMr, and whole 
brain volume and enlargement of the lateral and third ventricles. 
1 0 
Hirayasu 
2000(125) 
Gray matter volume FEP 44 22 Patients with schizophrenia have GM reductions in the left planum 
temporale and bilateral Heschl gyrus GM volume reduction. 
1 0 
Hoff 2000(126) Gray matter volume FEP 50 20 No significant correlations were observed between measures of 
untreated illness and the severity of structural brain deficit at the 
baseline. 
0 0 
Kumra 2000(12) Gray matter volume COP, ChP 71(33) 106 Patients had a smaller total cerebral volume and larger lateral 
ventricles than healthy comparison subjects.  
1 0 
Sowell 2000(29) VBM COP 9 10 Early-onset schizophrenia had larger ventricles, predominantly in the 
posterior horn of the lateral ventricles, and midcallosal, posterior 
cingulate, caudate and thalamic abnormalities.  
1 0 
Hirayasu 
1999(127) 
Gray matter volume FEP 41 20 Schizophrenia did not differ from comparison group in left subgenual 
cingulate volume. Left subgenual cingulate abnormalities are 
present in psychotic affective disorder and in patients with family 
history of affective disorder. 
2 3 
Rapoport 
1999(128) 
Gray matter volume COP 15 34 Childhood onset schizophrenia had a distinctive disease specific GM 
volume decrease mostly affecting frontal and temporal regions. 
1 0 
Robinson 
1999(129) 
Gray matter volume FEP 95 - MRI measures were not significantly predicting time to releapse 0 0 
Velakoulis 
1999(130) 
Gray matter volume ChP, FEP 78 140 Chronic schizophrenic and FEP had significantly bilaterally smaller 
hippocampal volumes as compared with controls.  
1 0 
Cannon 1998(47) Gray matter volume ChP, GHR 135(34) 56 Structural alteration of the cerebral cortex (frontal e temporal lobes) 
are present in patients with schizophrenia and in some of their 
siblings without schizophrenia, ventricular enlargement is unique to 
the clinical phenotype. 
2 2 
Hirayasu 
1998(131) 
Gray matter volume FEP 33 18 Temporal lobe abnormalities are present in schizophrenia. Low GM 
volume of the left posterior superior temporal gyrus is specific for 
schizophrenia compared with affective disorder. 
2 4 
Keshavan 
1998(132) 
Gray matter volume FEP 25 17 Both patient groups had bilaterally reduced caudate, but not 
putamen, volumes, compared to the healthy subjects. 
1 0 
Zipursky 
1998(133) 
Gray matter volume FEP  77 61 Patients had significantly smaller GM volume than normal controls. 
Within patients, GM volumes were positively correlated with IQ.  
1 0 
Frazier 
1996a(65) 
Gray matter volume COP 21 33 Brain anatomic abnormalities in childhood onset schizophrenia are 
similar to those reported for adult population. 
1 0 
Frazier 
1996b(66) 
Gray matter volume ChP 8 8 Caudate enlargement in patients with schizophrenia who are taking 
typical neuroleptics appears to be secondary to medication 
exposure. 
0 0 
Bilder 1994(134) Gray matter volume FEP 70 51 No volumetric differences but abnormal hemispheric asymmetry. 0 0 
Lieberman 
1993a(17) 
Gray matter volume FEP 66 - Frontal and parietal cortex, lateral ventricle, third ventricle, medial 
temporal lobe structures brain pathomorphology significantly 
predicted time to remission. 
0 0 
Lieberman 
1993b(25) 
Gray matter volume + 
eye tracking + 
dopamine activity 
FEP 66 42 Decreased GH response to apomorphine related to third ventricle 
enlargement. Morphologic abnormalities of the medial temporal lobe 
and third ventricle were associated with normal eye tracking. 
1 0 
Cohen 1988(24) Qualitative reading of 
CT and MRI 
Chronic 16 - MRI showed superiority to CT in visualization of midline structure. 
None of the findings from CT or MRI explained clinical observation 
or led to a change in treatment. 
0 0 
FEP, first episode psychosis; ChP: Chronic psychosis; CHR, Clinical High Risk; CHR-T, Clinical High Risk with subsequent Transition to psychosis; CHR-NT, Clinical High 
Risk without subsequent transition to psychosis; GHR, Genetic High Risk; COP: Childhood-Onset Psychosis; VBM: Voxel-Based Morphometry; GM: Gray Matter; WM: 
White Matter; (1) CHR-T 35, CHR-NT 239; (2) patients with Major Depressive Disorder; (3) CHR 89, FEP 23; (4) patients with Bipolar Disorder; (5) patients treated with 
antipsychotics 23, patients untreated 22; (6) some patients from the initial sample discharged because of imaging artifacts; (7) patients with non clinical auditory verbal 
hallucinations 50, patients with ChP and auditory verbal hallucinations 50; (8) ChP 351, GHR, 369; (9) FEP responders 40, FEP non responders 40; (10) patients not 
receiving mood stabilizers 118 vs patients receiving mood stabilizers 20; (11) CHR-T 48, CHR-NT 134; (12) at 52 weeks, FEP patients with herpes virus 1 12, without 
herpes virus 1 6, healthy controls with herpes virus 1 7, without herpes virus 1 17; (13) patients receiving Cognitive Enhancement Therapy 30 vs patients receiving Enriched 
Supportive Therapy 23; (14) GHR males 12, GHR females 14, healthy controls males 12 healthy controls females 14; (15) CHR early phase 20, CHR late phase 25; (16) 
CHR-T 15, CHR-NT 18; (17) CHR-T 12, CHR-NT 23, FEP 23; (18) 9 monozygotic and 10 dizygotic twin pairs discordant for schizophrenia; (19) patients with schizophrenia 
42, GHR of schizophrenic patients 57, patients with affective psychoses 38, GHR of patients with affective psychoses 52; (20) Chp 89, FEP 162, CHR 135, CHR-T 39; (21) 
COP 12, FEP 9; (22) duration of untreated psychosis less than 13 weeks 57 vs duration of untreated psychosis more than 13 weeks 48; (23) 25 patients had Schizotypal 
Personality Disorder; (24) (6) psychotic patients with high 34 vs low 35 Neurological Soft Signs; (25) COP 23, psychosis not otherwise specified 19; (26) patients with 
schizophrenia 25, GHR of schizophrenic patients 36, patients with affective psychoses 37, GHR of patients with affective psychoses 50; (27) ChP 64, GHR 46; (28) CHR-T 
23 vs CHR-NT 52; (29) ChP 64, GHR 51; (29) GHR 45, ChP 18; (30) ChP 72, GHR 58, Chp with fetal hypoxia 15, ChP without fetal hypoxia 52; (31) 16 patients had 
Schizotypal Personality Disorder; (32) affected vs unaffected siblings of patients with schizophrenia; (33) COP 44, psychosis not otherwise specified 27; (34) ChP 75, GHR 
60. 
Table II 
Source Positional statement addressing the clinical relevance of 
structural brain imaging in psychosis 
Frances(90) “None of the exciting scientific findings has had any impact 
whatever on the everyday practice of clinical psychiatry” 
Kapur(89) “Profusion of statistically significant, but minimally 
differentiating, biological findings” 
Insel(87) “Unlike our definitions of ischemic heart disease, lymphoma, or 
AIDS, the DSM diagnoses are based on a consensus about clusters 
of clinical symptoms, not any objective laboratory measure”. “It 
became immediately clear that we cannot design a [diagnostic] 
system based on biomarkers”. 
NICE(64) “Structural neuroimaging, using methods called magnetic 
resonance imaging (MRI) or computed axial tomography (CT) 
scanning, is not recommended for use routinely to examine all 
people who have had a first episode of psychosis” 
Fava(91) “Neurosciences have exported their conceptual framework into 
psychiatry much more than serving as an investigative tool for 
addressing the questions addressed by clinical practice” 
Parnas(135) “A psychiatrist treats a person and not a brain circuit. We will 
therefore continue to need a classification anchored in 
phenomenology, and into which the brain enters in so far that the 
neural pathology is diagnostically or therapeutically relevant to 
this suffering and not because the brain de jure is of principal 
interest for psychiatry” 
Figure 3. A) classification boundary is created based on the maximum margin space between 
data points. Only data points near the margin (the support vectors) affect the classification 
boundary, thus facilitating a good generalization of the classification boundary. B) If it is not 
possible to create a linear 2D classification boundary, a kernel function can be used to transform 
the data into higher dimensional space where classes become linearly separable. Bottom figure) 
schematic of SVM training and testing with neuroimaging data. In training, information from the 
two groups is used to make a classification algorithm based on the predictive differences of the 
two groups. In testing, the algorithm is applied to data from a new subject to classify them as 
belonging to either group. From(136) 
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